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Approximately 2% of colorectal cancer is linked to pre-existing inflammation known as colitis-associated cancer, but most develops in patients without underlying inflammatory bowel disease. Colorectal cancer often follows a genetic pathway whereby loss of the adenomatous polyposis coli (APC) tumour suppressor and activation of b-catenin are followed by mutations in K-Ras, PIK3CA and TP53, as the tumour emerges and progresses 1, 2 . Curiously, however, 'inflammatory signature' genes characteristic of colitis-associated cancer are also upregulated in colorectal cancer 3, 4 . Further, like most solid tumours, colorectal cancer exhibits immune/inflammatory infiltrates 5 , referred to as 'tumour-elicited inflammation' 6 . Although infiltrating CD4
1 T H 1 cells and CD8 1 cytotoxic T cells constitute a positive prognostic sign in colorectal cancer 7, 8 , myeloid cells and T-helper interleukin (IL)-17-producing (T H 17) cells promote tumorigenesis 5, 6 , and a 'T H 17 expression signature' in stage I/II colorectal cancer is associated with a drastic decrease in disease-free survival 9 . Despite its pathogenic importance, the mechanisms responsible for the appearance of tumour-elicited inflammation are poorly understood. Many epithelial cancers develop proximally to microbial communities, which are physically separated from immune cells by an epithelial barrier 10 . We investigated mechanisms responsible for tumour-elicited inflammation in a mouse model of colorectal tumorigenesis, which, like human colorectal cancer, exhibits upregulation of IL-23 and IL-17. Here we show that IL-23 signalling promotes tumour growth and progression, and development of a tumoural IL-17 response. IL-23 is mainly produced by tumour-associated myeloid cells that are likely to be activated by microbial products, which penetrate the tumours but not adjacent tissue. Both early and late colorectal neoplasms exhibit defective expression of several barrier proteins. We propose that barrier deterioration induced by colorectal-cancer-initiating genetic lesions results in adenoma invasion by microbial products that trigger tumour-elicited inflammation, which in turn drives tumour growth.
Specimens of human colorectal cancer (CRC) show increased expression of IL-23p19 and IL-17A messenger RNA (mRNAs) (Fig. 1a) . IL-23p19 is the specific subunit of IL-23, a positive regulator of T H 17 and other IL-17-producing cells 11 , previously found to promote skin carcinogenesis 12 . To address the role of these cytokines in CRC-related tumour-elicited inflammation and tumour growth, we used Apc F/wt mice that harboured a Cdx2-Cre transgene (CPC-APC mice) in which colorectal tumorigenesis was driven by Apc allelic loss 13 . Unlike Apc Min mice, CPC-APC mice develop tumours primarily in the distal colon, providing a relevant model of human CRC 13 . Mouse colon tumours also exhibited marked upregulation of IL-23 and IL-17A mRNA and IL-23 protein relative to matched non-tumour colon (Fig. 1b, c) . IL-23 induction was specific, as tumoural expression of other IL-12/23 family members was not substantially elevated and IL-23 itself was already seen in early tumours ( Supplementary Fig.  1a, b) . IL-23 expression did not further increase in more advanced mouse CRC caused by Apc loss and forced K-Ras or B-Raf activation ( Supplementary Fig. 1c ). Analysis of Il23 2/2 mice harbouring green fluorescent protein (GFP) gene in the Il23p19 locus, staining with IL23p19 antibody and flow cytometry showed that IL-23p19 is particularly expressed in tumour-infiltrating cells such as CD11b
1 and F4/80 1 myeloid cells ( Supplementary Fig. 1d-f ). Both IL-23 subunits, p19 and p40, need to be simultaneously expressed to generate a functional cytokine. Analysis by quantitative PCR with reverse transcription (RT-qPCR) and fluorescence-activated cell sorting (FACS) of tumoural cell populations showed that CD11b 1 cells expressed substantial amounts of both p19 and p40 (Fig. 1d) . T H 17-and other IL-17-producing cells were detected in mesenteric lymph nodes and tumours of CPC-APC mice and demonstrated dependence on IL-23 signalling (Fig. 1e) . Thus, expression of IL-23 and its downstream target IL-17A is increased during spontaneous colorectal tumorigenesis.
Colorectal tumour multiplicity and growth were diminished upon ablation of IL-23 or IL-23R in CPC-APC mice (Fig. 1f, g and Supplementary Fig. 2a) . Although intra-tumoural apoptosis was unaffected, cancer cell proliferation was reduced in Il23 2/2 /CPC-APC mice ( Supplementary Fig. 2b, c) . Epithelial STAT3 phosphorylation was decreased without IL-23, but genetically driven nuclear b-catenin accumulation was unaffected ( Fig. 1g and Supplementary Fig. 2d ). IL-23 signalling was important for intra-tumoural production of downstream cytokines, which are either direct (IL-6, IL-22) or indirect (IL-17A) STAT3 activators (Fig. 1h) . Pro-tumorigenic IL-23 signalling was particularly confined to the haematopoietic compartment, as CPC-APC chimaeras harbouring Il23 -/-or Il23r gfp/gfp bone marrow also exhibited reduced tumour load ( Supplementary Fig. 3a-d ) and diminished expression of IL-23-dependent cytokines ( Supplementary  Fig. 3e ). To examine the role of IL-17 signalling in CRC tumorigenesis, we crossed CPC-APC mice with Il17ra 2/2 mice, which do not respond to either IL-17A or IL-17F. Both tumour multiplicity and growth were reduced in the absence of IL-17RA ( Supplementary Fig. 4a-c) .
We examined the cause of IL-23 upregulation in CRC. The commensal microflora regulates basal colonic IL-23 expression in naive mice 14 . Microbial products are sensed by Toll-like receptors (TLRs), which rely on the adaptors MyD88 and TRIF 15 . Similar to its effect on small intestinal polyps in Apc Min mice 16 , whole body MyD88 ablation reduced tumour multiplicity and growth in CPC-APC mice (data not shown). We transplanted Myd88 2/2 , Tlr2,4,9 2/2 triple knockout or control bone marrow into lethally irradiated CPC-APC mice. Expression of IL-23p19 mRNA by sorted tumoural myeloid cells was decreased upon TLR/MyD88 inactivation in the haematopoietic compartment (Fig. 2a) . Intratumoural expression of IL-6 and IL-17A was also dependent on MyD88 in bone-marrow-derived cells (Fig. 2b) .
Transplantation with Myd88
-/-or Tlr2,4,9 2/2 bone marrow reduced colorectal tumour growth ( Fig. 2c and Supplementary Fig. 5 ). By contrast, deletion of IL-18R in bone marrow had no effect on tumorigenesis or IL-23 production by TAM ( Supplementary Fig. 6a, b) . Short-term depletion of intestinal microflora with a combination of broad-spectrum antibiotics, which reduced microbial counts by over 99.9%, also inhibited IL-23 expression by TAM, resulting in reduced tumoural IL-17A and decreased STAT3 activation in cancer cells (Fig. 2d-f) . Prolonged depletion of commensal microflora by antibiotic treatment 
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1 gate). f, Five-monthold Il23 2/2 and control CPC-APC mice were killed and tumour numbers, size and load were determined (n 5 7, P 5 0.04, 0.03, 0.01, respectively). g, Tumour sections were stained with haematoxylin and eosin or phospho-STAT3 and b-catenin antibodies. h, Cytokine mRNA analysis by RT-qPCR in mesenteric lymph nodes (MLN), normal (N) and tumour (T) tissue of 5-month-old Il23 2/2 and control CPC-APC mice (n 5 6, P 5 0.044, 0.007, 0.045, respectively). Data represent averages 6 s.e.m. *P , 0.05. Scale bars, 100 mm.
LETTER RESEARCH for 3.5 months starting at weaning reduced tumour size and load in control CPC-APC mice but not in Il23r
/CPC-APC counterparts (Fig. 2g) , emphasizing the importance of microbial product-driven IL-23 signalling.
By injecting fluorescein isothyocyanate (FITC)-labelled dextran into clamped colonic loops, we found that tumour development in CPC-APC mice was associated with translocation of FITC-dextran into the circulation (Fig. 3a) . This suggested that CRC development may result in increased penetration of microbial products or microbes into tumours. Indeed, Alexa488-labelled lipopolysaccharide (LPS) injected into colonic loops of CPC-APC mice translocated into tumours where it particularly co-localized with F4/80 1 TAMs, but did not penetrate adjacent normal tissue (Fig. 3b) . Tumour development also coincided with elevated endotoxin in portal blood (Fig. 3c) . Occasional bacteria were detected by in situ hybridization with a eubacterial 16S ribosomal RNA (rRNA) probe within colorectal tumours (Fig. 3d) and proximal to tumour epithelial cells in mouse early lesions that resembled aberrant crypt foci and early human adenomas (Fig. 3e, f) .
Mucus from goblet cells prevents bacterial penetration through the colonic epithelial barrier. Correspondingly, Muc2 2/2 mice develop spontaneous colitis followed by colitis-associated cancer 17, 18 . Periodic acid-Schiff staining indicated absence of mucus-producing cells and mucins in tumours but not in adjacent normal tissue (Fig. 4a) . Staining with wheat germ agglutinin (WGA) for glycosylated mucus proteins and mucin 2 (Muc2)-specific antibody demonstrated markedly reduced Muc2 production and coating of tumour tissue (Fig. 4a) . Muc2 was barely detected in human CRC, but was prominent in adjacent normal tissues (Fig. 4b) . Muc2 mRNA was downregulated in human and mouse colorectal tumours relative to healthy tissues ( Supplementary Fig. 7a, b) . Epithelial barriers also depend on tight and adherent junctions 10 . Human CRC demonstrated notable loss of polarized expression of junctional proteins JAM-A and JAM-B (Fig. 4c) . JAM-A/B mRNAs were also reduced in human CRC and JAM-C mRNA was downregulated in mouse tumours ( Supplementary  Fig. 7a , b) Although claudin 4 mRNA was not downregulated in human or mouse tumours ( Supplementary Fig. 7a, b) , the protein was no longer distinctly localized to tight junctions in human or mouse tumours, similar to claudins 3, 5 and 7 ( Supplementary Fig. 8a, b) . Early human adenomas also showed defective mucin expression and organization of tight junctions (Fig. 4d) , coinciding with elevated IL-23 ), representative of two independent experiments, each including four pooled mice (a) or in tumours and normal tissues (n 5 5, P 5 0.004, 0.032) (b). c, Tumour number, size and load in mice transplanted with indicated bone marrow (n 5 5, P 5 0.14, 0.048, 0.046, respectively). BMT, bone marrow transfer. d-f, CPC-APC mice were treated with a cocktail of antibiotics (Abx) for 3 weeks. d, Myeloid cells were sorted from tumours and analysed by RT-qPCR, representative of two independent experiments, each including four pooled mice. e, IL-17A mRNA expression in normal and tumour tissues from the control and Abx-treated CPC-APC mice (n 5 9, P 5 0.003). f, Colon sections from mice were stained with phospho-STAT3 antibody, and intensity of staining was quantified (n 5 8, P 5 0.049). g, WT (Il23r
2/2 CPC-APC mice were treated with antibiotics for 3.5 months and tumour size and load were determined (n 5 5, P 5 0.027 and 0.043). Data represent averages 6 s.e.m. *P , 0.05. Scale bars, 50 mm.
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and IL-17A in adenoma tissue (Supplementary Fig. 9a ). Early CRC lesions, such as aberrant crypt foci, are marked by enhanced expression and nuclear translocation of b-catenin, and such areas were devoid of WGA and JAM-A staining (Fig. 4e) . To demonstrate further that barrier loss is an early and direct consequence of tumour emergence, we studied rapid colonic transformation in Cdx2 ERT-Cre 3 Apc F/F mice using tamoxifen to induce bi-allelic APC inactivation. APC loss resulted in patches of proliferating transformed cells with enlarged nuclei, which coincided with loss of mucin and induction of IL-23 ( Fig. 4f and Supplementary Fig. 9b ). Nearly all solid malignancies contain inflammatory infiltrates, influencing tumour promotion, progression and metastasis 5, 6 . The contribution of inflammation to CRC pathogenesis is emphasized by the protective effect of non-steroidal anti-inflammatory drugs, such as aspirin 19 , but sources of tumour-elicited inflammation in CRC were heretofore unknown. We now suggest that early CRC-inducing genetic events may cause local loss of barrier function and entry of microbial products into the tumour microenvironment. This results in activation of IL-23-producing myeloid cells, which regulate expression of downstream tumour-promoting cytokines, including IL-17 and IL-6. A similar mechanism may apply to other cancers that develop in epithelia that are exposed to commensal and pathogenic bacteria. Deregulation of tight junctions and cell-cell contacts was described in advanced human adenocarcinomas, but suggested to cause detachment of carcinoma cells from their neighbours, increased motility and metastasis 20 . The importance of the mucus layer is emphasized by whole body Muc2 deficiency, which causes colonic inflammation 17, 18 . Prolonged treatment with dextran sulphate sodium, which promotes development of colitis-associated cancer in wild type (WT) or Apc Min mice, also causes erosion of the intestinal epithelial barrier and microbialdependent inflammation 21, 22 , and so do the barrier-disrupting pathogens Citrobacter rodentium 23 and enterotoxic Bacteroides fragilis 24 . The commensal microflora was suggested to promote adenoma development, as germ-free Apc Min mice exhibit a twofold reduction in small intestinal adenomas 25 and Tbx21
2/2
;Rag2 2/2 ulcerative colitis (TRUC), and Il10 2/2 mice fail to develop colitis-associated cancer when rendered germ-free 26, 27 . Our work demonstrates that defective expression of barrier proteins is an early event in CRC tumorigenesis, coupled to upregulation of IL-23 and its downstream cytokines. We also found that IL-23 does not act directly on adenoma cells and that its receptor is expressed and signals within the haematopoietic compartment. Probably, IL-23 acts through IL-17 family members, as ablation of IL-17R attenuated colorectal tumorigenesis. IL-23 is instrumental for stabilizing the 'T H 17 signature', which includes IL-17A, RORct and IL-23R, and was linked to extremely poor prognosis in human stage I/II CRC, which otherwise show 75-90% survival 9 . IL-23 itself is not a part of the 'T H 17 signature', arguably because its expression is already elevated in early colorectal tumours. The 'IL-23/T H 17' and 'T H 1-cytotoxic' signatures are not mutually exclusive in human CRC 9 . Although in genetically uniform mice in barrier facilities IL-23 invariably leads to IL-17 induction, the genetic heterogeneity of human populations and their exposure to a broader spectrum of microbes may explain why certain individuals mount a stronger T H 17 response than others. T H 17 development is promoted by several cytokines, including IL-21, IL-6 and IL-1, all of which can be induced by microbial components 28 . It remains to be investigated which of these cytokines contributes to the tumoural T H 17 response and how it is affected by distinct microflora components. Segmented filamentious bacteria persisting in proximity to epithelial cells initiate T H 17 responses in the small intestine 29 . In tumours lacking protective barrier, other microbial species and products may invade the tumour and influence the 'IL-23/T H 17' signature.
Loss of APC and activation of b-catenin induces a proliferative state and blocks the differentiation of certain IEC lineages, including mucin-producing goblet cells 30 . Epithelial barrier loss may therefore be a consequence of b-catenin activation and/or of APC loss, which apart from b-catenin can also control cytoskeleton dynamics. Hence, early barrier loss and activation of IL-23/IL-17-driven tumour-elicited inflammation act additively and sequentially to genetically controlled events that govern CRC development and progression (Supplementary Fig. 10 ). We propose that screening of early tumours for IL-17 expression and adjuvant treatment of patients showing a 'T H 17 signature' with IL-23 or IL-17 antagonists should reduce mortality due to CRC.
METHODS SUMMARY
Mice were backcrossed to the C57BL/6 background for at least seven (CPC-APC) or ten (others) generations and maintained and studied in filter-topped cages on autoclaved food and water in a barrier facility at the University of California, San Diego, according to institutional and National Institutes of Health (NIH) guidelines. Male and female mice were used in this study, including littermate and cage mate controls. Il23r F/F mice were generated by C.A.S., L.T., V.C. and G.T. (Supplementary Fig. 11 ). Cdx2
ERT-Cre mice were generated and maintained by Y.F. and E.R.F. and will be reported elsewhere. Mice were allowed to develop spontaneous CRC for 4-5 months. At the end of each study, mice were killed and colonic tumours and non-tumour tissue, along with mesenteric lymph nodes, were analysed using flow cytometry, enzyme-linked immunosorbent assay (ELISA), RT-qPCR, immunohistochemistry and fluorescent microscopy. Lethally irradiated (2 3 600 rad) littermate CPC-APC recipient mice were intravenously injected with 10 7 nucleated bone marrow cells from various donors to generate radiation chimaeras. Endotoxin was measured in portal vein blood/ plasma by a Limulus assay. For intestinal permeability analysis, tumour-bearing and control mice were surgically clipped and FITC-dextran or Alexa488-LPS were injected into the colonic lumen, followed by fluorescent detection of FITC in serum or Alexa488-LPS in frozen colon sections.
METHODS
Human samples. Paraffin-embedded human ulcerative colitis and CRC specimens were provided by Oberndorf Hospital, Paracelsus Medical University Salzburg, Austria. Patients with ulcerative colitis or sporadic CRC underwent colonoscopy as a part of the diagnostic workup at the Department of Internal Medicine, Oberndorf Hospital (Salzburg, Austria). Diagnosis of ulcerative colitis was based on appropriate clinical, endoscopic, histopathological and radiological findings that satisfied the internationally accepted Lennard-Jones criteria 31 . Additionally, colonoscopic findings were classified as tubular adenoma, size less than 6 mm (early lesion), advanced adenoma (that is, villous or tubulovillous features), size at least 1 cm or high-grade dysplasia or carcinoma after a combined analysis of macroscopic and histological results 32, 33 . Biopsies from colonic tissue with macroscopically normal appearance were taken in patients who underwent colonoscopy for CRC screening. For histological examination, specimens were fixed in 4% buffered formalin and embedded into paraffin. When available, a small tissue portion of the biopsy specimen was separated and preserved for RNA and protein extraction in RNAlater (Ambion's RNAlater solution, Applera, Brunn am Gebirge, Austria). Biopsies from colonic tissue with macroscopically normal appearance were taken in patients who underwent colonoscopy for CRC screening. Written informed consent was obtained from all study participants to use one biopsy specimen for scientific purposes. Fig. 11a ). The targeting vector was generated by recombineering using l phage Red as described by Liu et al.
34
. Homology arms for the retrieval vector were amplified by PCR on C57BL/6 genomic DNA. Homology arms were cloned into pLMJ235 (pBSKS1 containing a 2.8kb SalI TK fragment of pGKTK) by triple ligation to form the retrieval plasmid. Retrieval of the targeting region (covering 753-12,812; numbering relative to indicated BamHI site) was performed according to Liu et al. 34 using C57BL/6 bacterial artificial chromosome RP23-283M8 (BACPAC Resources) as template in DY380 cells. Recombineering was performed to insert cassettes containing LoxP-flanked Neo cassettes from pGKEM7Neo-pA into the targeting vector. First, LoxP-Neo-LoxP was inserted at position 3,524, followed by induced expression of Cre in EL350 cells to excise the Neo selection cassette but leaving the upstream LoxP site. A second cassette (LoxP-Frt-Intron-Eng2SA-NeoLoxP-Frt) was inserted into position 8,503. After NotI-linearization, the targeting construct was electroporated into Bruce 4 C57BL/6 ES cells, and G418-selected clones were screened for integration by Southern analysis using sequences outside the targeting vector ( Supplementary Fig. 11b ). Selected clones were injected into C57BL/6-albino blastocysts and transferred to pseudopregnant females. Chimeric offspring were bred with C57BL/6-Albino partners to generate F 1 mice that were screened for integration by Southern blotting (Supplementary Fig. 11c ). Resulting mice with the Il23r SA-F-neo allele were crossed with C57BL/6-FLPe mice to facilitate recombination between Frt sequences and generate the Il23r F allele. The null allele (Il123r 2/2 ) was generated by crossing Il23r F/F mice with CPC-Cre transgenic mice. The F 2 generation exhibits germline deletion of floxed alleles owing to early CPCCre expression in caudal regions of the body and gonads 13 . Complete ablation of IL-23R was confirmed by RT-qPCR of spleen and tumour-derived cells. Animal models. C57BL/6 control mice obtained from Charles River Laboratories were bred locally at University of California, San Diego. were from H. Hoffman. All mice were maintained in filter-topped cages on autoclaved food and water at University of California, San Diego, according to NIH guidelines, and all experiments were performed in accordance with University of California, San Diego, and NIH guidelines and regulations. Most experiments used littermate controls housed in the same cage; in addition, dirty beddings were switched between cages of the same experiment to make sure that the microflora was balanced. For spontaneous CRC tumorigenesis, male and female CPC-APC mice were allowed to develop colorectal tumours spontaneously for 4-5 months and then killed. Macroscopic tumours were counted and their diameter measured with a calliper. Average tumour size per individual mouse was determined by averaging diameters of all tumours present. Tumour load was determined as the sum of the diameters of all tumours presented in a given mouse, as previously described 41 .
Typically, one-half of the distal colon was taken as a tissue sample, tumours and normal tissue dissected and snap-frozen in liquid nitrogen or used for ex vivo cultures or fluorescence-activated cell sorting. The other half was fixed in 10% neutral buffered formalin for 24 h and transferred to 70% ethanol for subsequent paraffin embedding, or alternatively frozen in optimal cutting temperature (OCT) compound for further sectioning and histological analysis.
To induce colorectal tumours with inactivated Apc and activated K-Ras or B-Raf, open laparotomies were performed in mice bearing floxed Apc (Apc F/F ) in combination with either latent Kras G12D (Apc-Kras) or Braf V600E (Apc-Braf) alleles under isofluorane anaesthesia. A dosage of adenovirus-Cre was administered to the distal colon, which resulted in solitary colonic tumours, as described 42, 43 . Subsequent tumour formation was monitored by serial optical colonoscopy. Tumours were collected after more than 75% occlusion of the colonic lumen was observed and banked in RNA later for subsequent analysis. Colonic loops and injections of FITC-dextran and Alexa488-LPS. After anaesthesia, a midline laparotomy incision was made. A 2-3 cm long segment of the colon with or without tumours inside was created with two vascular haemoclips without disrupting the mesenteric vascular arcades. The length of intestine between the two clips was injected with 50 ml of 100 mg ml 21 FITC-dextran solution or 50 ml of Alexa488-LPS at 70 mg per mouse. At the indicated time points, mice were killed and fluorescence was measured in the plasma with a fluorimeter, or colon fragments were embedded into OCT compound, and frozen sections prepared and analysed for Alexa488-LPS tissue distribution by fluorescent microscopy.
